Caris study finds whole exome TMB predicts pembrolizumab survival better than gene panels

Caris Life Sciences, Inc.

Caris Life Sciences, Inc.

CAI

0.00
  • Caris Life Sciences published a study in Cancer Immunology, Immunotherapy showing whole exome sequencing-based measurement of tumor mutational burden better identified patients likely to benefit from pembrolizumab than estimates derived from targeted gene panels.
  • Findings were published with no separate conference presentation disclosed.
  • Analysis of 26,756 pembrolizumab-treated patients found targeted panels sometimes misclassified patients, which could shift immunotherapy eligibility decisions.
  • In cases where panel estimates diverged from whole exome results, whole exome-based assessment aligned more closely with improved survival outcomes.
  • Results support broader adoption of whole exome sequencing in therapy selection, reinforcing commercial positioning of its FDA-cleared MI Cancer Seek assay that reports tumor mutational burden.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605111215PR_NEWS_USPR_____DA56262) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.